Merck says experimental skin disease drug meets main goal in mid-stage study

Merck said on Wednesday its experimental ​drug met the main goal ‌of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, ​a chronic skin disease ​that causes painful lumps,...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。